Real-world use of BCL-2 inhibitor regimens in CLL/SLL

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational, non-interventional cohort gathers data from participating centers to describe patient demographics, disease features, treatment exposure, effectiveness outcomes, and safety for BCL-2 inhibitor–based regimens in CLL/SLL. It uses routine clinical data to characterize treatment patterns and real-world outcomes. The study aims to inform clinical decision-making and help optimize patient management outside of controlled trials. Data will include baseline characteristics and at least one evaluable follow-up record on effectiveness, safety, or survival.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥18 years at the time of enrollment;
* Confirmed diagnosis of CLL or SLL according to the 2018 iwCLL criteria;
* Prior or ongoing treatment with a BCL-2 inhibitor-based regimen;
* Availability of complete key baseline data (e.g., demographic characteristics, disease stage, molecular genetic features, and relevant laboratory parameters) and at least one evaluable post-treatment follow-up record, including effectiveness assessment, safety evaluation, or survival data.

Exclusion Criteria:

* Patients with significant missing key baseline information or treatment exposure data, rendering evaluation of effectiveness or safety outcomes not feasible.

Where it's running

• Jiangsu Province Hospital
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: Huayuan ZHU
• Email: huayuan.zhu@hotmail.com
• Phone: +86-13813810650

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Rocbrutinib versus pirtobrutinib for adults with relapsed or refractory CLL/SLL after a covalent BTK inhibitor

  This compares rocbrutinib and pirtobrutinib to see which works better and is safer for adults whose CLL or SLL returned or didn't respond after a covalent BTK inhibitor.

  Recruiting at 6 sites Phase 3 Newave Pharmaceutical Inc · Skokie, Illinois and 6 other locations · NCT07342478

• ZE50-0134 for relapsed or refractory CLL, SLL, and select low-grade lymphomas

  This study tests whether a new drug called ZE50-0134 is safe and has anti-lymphoma activity in adults with relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma, or certain low-grade lymphomas.

  Recruiting at 4 sites Phase 1 Lomond Therapeutics Holdings, Inc. · Louisville, Kentucky and 4 other locations · NCT06708897

• Epcoritamab given after 2nd-generation BTK inhibitors for CLL/SLL

  This trial will try giving subcutaneous epcoritamab for up to 12 cycles to adults with CLL/SLL who have been on a second‑generation BTK inhibitor for at least 12 months to see if it can deepen responses to a complete remission with undetectable MRD so therapy can be stopped.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT07108998

• LP-168 plus obinutuzumab for previously treated and BTK T474I‑mutated CLL/SLL

  This trial tests whether adding LP-168 to obinutuzumab helps people with previously treated CLL/SLL, including those with the BTK T474I gatekeeper mutation, achieve deeper remissions.

  Recruiting Phase 2 University of Cincinnati · Cincinnati, Ohio · NCT06978088

• Combining Lisaftoclax and Acalabrutinib for Newly Diagnosed CLL/SLL

  This study is testing if a new combination of two drugs, Lisaftoclax and Acalabrutinib, can work better than standard treatment for people who have just been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 3 Ascentage Pharma Group Inc. · Bengbu, Anhui and 9 other locations · NCT06319456

• Investigating a new treatment for patients with CLL/SLL

  This study is testing if a new treatment combining lisaftoclax with BTK inhibitors can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have already been treated with BTK inhibitors.

  Recruiting at 120 sites Phase 3 Ascentage Pharma Group Inc. · Tuscon, Arizona and 134 other locations · NCT06104566

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.